Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…Abstract Number: 1964 • 2014 ACR/ARHP Annual Meeting
Changes in Soluble CD18 Reflect Latency in the Immune System and Predict Radiographic Progression in Early Rheumatoid Arthritis
Background/Purpose In early rheumatoid arthritis (RA), clinical disease characterized by swollen and painful joints is caused by synovitis. However, presence of autoantibodies may precede the…Abstract Number: 1473 • 2014 ACR/ARHP Annual Meeting
Manocept-Cy3 Localizes CD206 + Macrophages in Synovial Tissue and Fluid from Rheumatoid Arthritis Patients Differentially Compared to Controls
Background/Purpose: Early identification of rheumatoid arthritis (RA) would allow aggressive treatment with disease modifying rheumatic drugs and provide a system to monitor patient responses. Therefore,…Abstract Number: 920 • 2014 ACR/ARHP Annual Meeting
Randomized Controlled Trial to Assess the Safety and Efficacy of Odanacatib in the Treatment of Men with Osteoporosis
Background/Purpose Osteoporosis in men is an important clinical problem, associated with significant morbidity, mortality and societal expense. Men with osteoporosis represent between 20 and 25%…Abstract Number: 400 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of 14-3-3η in the Evaluation of Inflammatory Arthritis
Background/Purpose 14-3-3 proteins are chaperonins found in all eukaryotic cells. There are multiple isoforms which are thought to be involved in intracellular signaling and transcription…Abstract Number: 2927 • 2014 ACR/ARHP Annual Meeting
Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis
Background/Purpose Response to tumor necrosis factor alpha (TNF-α) inhibition is variable in rheumatoid arthritis (RA). Previous studies have suggested that circulating type I interferon (IFN)…Abstract Number: 1921 • 2014 ACR/ARHP Annual Meeting
The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus
Background/Purpose: We sought to evaluate the usefulness of cell bound complement activation products (C4d deposition on erythrocytes [EC4d] and platelets [PC4d]) in the monitoring of…Abstract Number: 1462 • 2014 ACR/ARHP Annual Meeting
Cadherin-11 mRNA Expression in the Peripheral Blood of Rheumatoid Arthritis Patients As a Marker of Active Polyarthritis
Background/Purpose: Human rheumatoid arthritis synovial fibroblasts (RASF) implanted subcutaneously in immunodeficient mice trans-migrate through the vasculature and drive the progression from oligo- to poly-articular disease.…Abstract Number: 914 • 2014 ACR/ARHP Annual Meeting
A Predictive Model of Disease Outcome in Rituximab-Treated Myositis Patients Using Clinical Features, Autoantibodies, and Serum Biomarkers
Background/Purpose: Develop predictive models of early (8 week) and late (24 week) disease outcomes using clinical features, autoantibodies, and serum biomarkers in patients with refractory…Abstract Number: 392 • 2014 ACR/ARHP Annual Meeting
Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis – Do Free Fatty Acids Play a Role?
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease associated with several neuroendocrine hormones and metabolic peptides. The crosstalk between the hormones and the immune…Abstract Number: 2928 • 2014 ACR/ARHP Annual Meeting
Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial
Background/Purpose . The recent discovered cytokine interleukin-33 (IL33) could be involved in B-cell activation as well as in RA pathophysiology. After a whole-blood transcriptomic analysis…Abstract Number: 1902 • 2014 ACR/ARHP Annual Meeting
Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity
Background/Purpose GlycA is a novel inflammatory biomarker measured from the nuclear magnetic resonance (NMR) spectra obtained for lipoprotein particle analysis. It represents a distinct peak…Abstract Number: 1408 • 2014 ACR/ARHP Annual Meeting
Inflammatory Biomarkers, Sleep Quantity and Sleep Quality in Rheumatoid Arthritis
Background/Purpose: Sleep problems affect over 60% of rheumatoid arthritis (RA) patients. However, little is known about the association between sleep problems and inflammatory pathways in…Abstract Number: 808 • 2014 ACR/ARHP Annual Meeting
Biomarkers of Disease Activity in Vasculitis
Background/Purpose To identify circulating proteins that distinguish between active vasculitis and remission in giant cell arteritis (GCA), Takayasu's arteritis (TAK), polyarteritis nodosa (PAN) and eosinophilic…Abstract Number: 368 • 2014 ACR/ARHP Annual Meeting
Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is partly characterized by joint destruction. Personalized health care is needed in RA to enable i) prediction of those patients that…
- « Previous Page
- 1
- …
- 70
- 71
- 72
- 73
- 74
- …
- 83
- Next Page »